

August 26, 2023

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Outcome of Board Meeting held on Saturday, August 26, 2023

Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we would like to inform you that the Board of Directors of Zota Health Care Limited (the “Company”) in its Meeting held on Saturday, August 26, 2023 at 3:30 P.M. at the Zota House, Bhagwan Aiyappa Complex, Next to Batliboi, Udhna-Navsari State Highway, Surat – 394210, Gujarat, have, *inter alia*, discussed and approved following businesses:

1. Board has given node for incorporating a Subsidiary Company with the name and style of ‘ZOTA NEX TECH LIMITED’ having a total capital of Rs. 10 lakh, by making an investment of Rs. 6,50,000; Company shall subscribe 65% of paid up share capital, that is 65,000 equity shares of Rs. 10/- each of the ZOTA NEX TECH LIMITED.
2. On the recommendation of Nomination & Remuneration Committee, the Board of Directors of the Company have appointed Mr. Laxmi Kant Sharma (DIN: 10266796) as an Additional Director to be designated as an Executive Director of the Company w.e.f. August 26, 2023 who shall hold office upto the date of the ensuing Annual General Meeting of the Company and subject to the approval of the members in the ensuing Annual General Meeting to hold office for a term of 5 (five) consecutive years, that is upto August 25, 2028.
3. On the recommendation of Nomination & Remuneration Committee, the Board of Directors of the Company have appointed Mr. Dhaval Chandubhai Patwa (DIN: 10283028) as an Additional Director to be designated as Non-Executive Independent Director on the Board of the Company w.e.f. August 26, 2023, who shall hold office upto the date of the ensuing Annual General Meeting of the Company and subject to the approval of the members in the ensuing Annual General Meeting to hold office for a term of 5 (five) consecutive years, that is upto August 25, 2028.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 are annexed herewith as **Annexure-I, and Annexure – II.**

Registered Office:

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com
CIN: L24231GJ2000PLC038352

The Board meeting concluded at 4:20 P.M.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

Ashvin Variya
(Company Secretary & Compliance Officer)

Place: Surat

Encl: a/a

Annexure – I

Particulars	Details
Name of the target entity, details in brief such as size, turnover etc	Name: ZOTA NEX TECH LIMITED as approved by the Ministry of Corporate Affairs. Authorized Capital: ₹ 10,00,000/- Turnover: Not Applicable since the Company is yet to be incorporated.
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	The subsidiary company once incorporated will be related party of the Company.
Industry to which the entity being acquired belongs	Tech
Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The proposed company will provide ERP solutions to the Company and its subsidiaries both frontend and backend and at later stage it will provide various data centric solutions including App developments.
Brief details of any governmental or regulatory approvals required for the acquisition	N.A.
Indicative time period for completion of the acquisition	N.A.
Nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration by way of acquisition of Equity Shares
Cost of acquisition or the price at which the shares are acquired	N.A.
Percentage of shareholding / control acquired and / or number of shares acquired	65%
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not applicable since the Company is yet to be incorporated.

Annexure – II

Particulars	Details	
	Mr. Laxmi Kant Sharma	Mr. Dhaval Chandubhai Patwa
Name of Director/ Nature of Directorship	Mr. Laxmi Kant Sharma, Additional Director in capacity of Executive Director (DIN: 10266796)	Mr. Dhaval Chandubhai Patwa, Additional Director in capacity of Non-Executive Independent Director (DIN: 10283028)
Reason for change	Appointment	Appointment
Date of Appointment and term of Appointment	Appointed w.e.f. August 26, 2023, upto the date of the ensuing Annual General Meeting of the Company and subject to the approval of the members, to hold office for a term of 5 (five) consecutive years, i.e upto August 25, 2028.	Appointed w.e.f. August 26, 2023, upto the date of the ensuing Annual General Meeting of the Company and subject to the approval of the members, to hold office for a term of 5 (five) consecutive years, i.e upto August 25, 2028.
Brief profile (in case of appointment)	Mr. Laxmi Kant Sharma holds Bachelor's degree of B.Sc. in Biology from Rajasthan University, Jaipur. He has also done Diploma in Pharmacy from Board of Technical Examinations, Maharashtra. He have acquired a strong foundation in field of retail pharmacy. His professional journey has been marked by diverse roles, ranging from serving as a Medical Representative and Area Sales Manager for 6 years in various pharma companies, to contributing as a pharmacist in a Retail Pharmacy setting for 15 years. He is also associated with the Company from the year 2018 as Manager in Operations of Davaindia stores. He is equipped with a comprehensive understanding of both business and healthcare aspects of the pharmaceutical industry.	Mr. Dhaval Chandubhai Patwa is fellow member of the Institute of Chartered Accountant of India (ICAI). He has completed Chartered Accountancy course in the year 2011. Along with that he has gained Diploma in Information Systems Audit. He has also done Bachelor of Commerce from the Veer Narmad South Gujarat University, Surat in the year 2010. Post qualification of Chartered Accountant he in 2011 he has formed his own firm and doing practice. So, he is having total work experience of around 12 years. His core areas of working are Direct and Indirect Taxes, Bank Audits, Management and System Audit, Accounting and Corporate Services.
Disclosure of Relationship between Directors (in case of appointment)	Mr. Laxmi Kant Sharma is not related to any Director(s) of the Company, and is not debarred from holding the office of director by virtue of any SEBI order or any other statutory authority.	Mr. Dhaval Chandubhai Patwa is not related to any Director(s) of the Company, and is not debarred from holding the office of director by virtue of any SEBI order or any other statutory authority.